











































































































Hb ９．８ g/dl TP ６．６ g／dl
RBC ３３０×１０４ ／μl ALB ３．４ g／dl
Ht ２９．２％ BUN １５mg／dl
WBC ３４１０ ／μl Cr ０．９９mg／dl
blast ８％ UA ４．５mg／dl
stab １５％ Na １４０mEq／L
seg ２０％ K ３．７mEq／L
eosino ０％ Cl １０１mEq／L
baso ０％ CRP １８．６９mg／dl
mono ０％ ATLA －
lymph ５５％
Plt ３．８×１０４ ／μl Bone marrow
blast :
PT １０５％ MPO negative





GOT ６５ IU／L +８，t（９；２２）（q３４；q１１．２），
GPT ５６ IU／L +１０，+１９，+der（２２）t（９；２２）
LDH １３９５ IU／L ［２］／４６，XX［１８］
ALP ９８８ IU／L






dasatinib 内服に vindesine を追加することにより一時的
な効果をみとめたが，再燃を繰り返し経過した．Day１６９
に多量の新鮮下血を来した．
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Tokushima Red Cross Hospital Medical Journal
Lower gastrointestinal bleeding in a patient with Philadelphia
chromosome-positive acute lymphoblastic leukemia receiving dasatinib
Keiji OZAKI, Hirofumi BEKKU, Naoko ISHIBASHI, Tomoko HARA, Tetsuya GOTO
Division of hematology, Tokushima Red Cross Hospital
The second-generation tyrosine kinase inhibitor, dasatinib induces responses in patients with imatinib
resistant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
（Ph+ALL）. We report a case of Ph+ALL complicated with lower gastrointestinal bleeding during administra-
tion of dasatinib. The case was a ５９-year-old woman with Ph+ALL treated with chemotherapy by addition of
imatinib. She relapsed during consolidation chemotherapy with imatinib. CNS involvement was also detected.
A BCR-ABL kinase point mutation was not observed. Treatment with dasatinib was started and a hematologic
response with improvement of CNS leukemia was observed. However, remission was not achieved, the leuke-
mic cell count increased gradually３months later. A small amount of bloody stool was observed１６０days after
therapy, and hemorrhagic shock with fresh lower gastrointestinal bleeding developed on the１６９th day. Dasatinib
was discontinued. Emergency colonoscopy under supportive therapy with red blood cell transfusion revealed
small erosive lesions of the mucosa, but no remarkable bleeding site was detected even at the second-look
examination. Bleeding episodes have been reported to occur during dasatinib therapy, particularly in patients
with low platelet counts or those who are in an aggressive state. Careful attention to bleeding diathesis is
required during dasatinib therapy.
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